We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+15.27%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$17.3B
AUM Growth
+$1.38B
Cap. Flow
-$440M
Cap. Flow %
-2.54%
Top 10 Hldgs %
32.07%
Holding
728
New
61
Increased
216
Reduced
343
Closed
55

Top Buys

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$85M
2
ABT icon
Abbott
ABT
+$53.8M
3
EXC icon
Exelon
EXC
+$46.6M
4
BSX icon
Boston Scientific
BSX
+$42.6M
5
ABBV icon
AbbVie
ABBV
+$32.4M

Top Sells

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$80.5M
2
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$54.5M
3
CRWD icon
CrowdStrike
CRWD
+$45.7M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$40.6M
5
MRK icon
Merck
MRK
+$39.3M

Sector Composition

Rank Sector Weight
1 Technology 36.26%
2 Healthcare 22.78%
3 Financials 10.33%
4 Consumer Discretionary 7.75%
5 Industrials 7.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ABNB icon
401
Airbnb
ABNB
$90.9B
$3.4M 0.02%
25,662
-514
-2% -$65.1K
PEN icon
402
Penumbra
PEN
$12.6B
$3.37M 0.02%
+13,148
New +$3.58M
ENIC icon
403
Enel Chile
ENIC
$6.05B
$3.37M 0.02%
928,000
+183,000
+25% +$647K
KVUE icon
404
Kenvue
KVUE
$37.9B
$3.31M 0.02%
158,322
+23,270
+17% +$529K
MTB icon
405
M&T Bank
MTB
$36.6B
$3.3M 0.02%
16,997
-92,175
-84% -$16.3M
HBAN icon
406
Huntington Bancshares
HBAN
$35B
$3.29M 0.02%
196,043
+15,723
+9% +$237K
GEN icon
407
Gen Digital
GEN
$16.6B
$3.28M 0.02%
111,716
-4,713
-4% -$129K
O icon
408
Realty Income
O
$61.3B
$3.28M 0.02%
56,898
-28,468
-33% -$1.61M
BKR icon
409
Baker Hughes
BKR
$58B
$3.24M 0.02%
84,377
-10,648
-11% -$402K
EOG icon
410
EOG Resources
EOG
$74.4B
$3.22M 0.02%
26,934
-8,096
-23% -$925K
EXPD icon
411
Expeditors International
EXPD
$22.4B
$3.18M 0.02%
27,802
+767
+3% +$85.9K
GPK icon
412
Graphic Packaging
GPK
$3.45B
$3.17M 0.02%
150,536
-17,300
-10% -$400K
ARES icon
413
Ares Management
ARES
$28.8B
$3.14M 0.02%
+18,114
New +$2.86M
DAR icon
414
Darling Ingredients
DAR
$9.28B
$3.12M 0.02%
82,306
-1,997
-2% -$65.7K
HUBB icon
415
Hubbell
HUBB
$25.6B
$3.12M 0.02%
7,643
+1,163
+18% +$431K
MSCI icon
416
MSCI
MSCI
$42.1B
$3.08M 0.02%
5,346
-766
-13% -$424K
COGT icon
417
Cogent Biosciences
COGT
$6.95B
$3.07M 0.02%
+427,342
New +$2.37M
PCAR icon
418
PACCAR
PCAR
$72.7B
$3.04M 0.02%
31,988
-6,176
-16% -$571K
NRIX icon
419
Nurix Therapeutics
NRIX
$2.51B
$2.99M 0.02%
262,384
-326,547
-55% -$3.53M
TROW icon
420
T. Rowe Price
TROW
$26.1B
$2.98M 0.02%
30,931
+5,236
+20% +$481K
IMNM icon
421
Immunome
IMNM
$2.63B
$2.96M 0.02%
+318,086
New +$2.61M
EIX icon
422
Edison International
EIX
$30.7B
$2.95M 0.02%
57,085
+866
+2% +$47.5K
EWTX icon
423
Edgewise Therapeutics
EWTX
$4.34B
$2.94M 0.02%
223,990
-1,806
-0.8% -$26K
PSX icon
424
Phillips 66
PSX
$82.5B
$2.93M 0.02%
24,522
-1,750
-7% -$196K
PCG icon
425
PG&E
PCG
$39.2B
$2.92M 0.02%
209,684
+10,543
+5% +$171K

Similar funds

Candriam SCA's Q2 2025 Portfolio in Review

As of Q2 2025, Candriam SCA held 728 positions worth $17.3B, up 8.6% from $16B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Candriam SCA's Q2 2025 filing shows 61 new, 216 increased, 343 reduced and 55 closed positions. Its largest new stake was Tapestry: 260,834 shares worth $22.9M. The largest sale was Tesla, an estimated $80.5M.

By sector, the portfolio is most concentrated in Technology at 36% of assets, up from 32% a quarter earlier, followed by Healthcare and Financials.

  • Candriam SCA's largest Q2 2025 buy was Tapestry: 260,834 shares worth $22.9M.
  • Candriam SCA added most to Broadcom in Q2 2025, an estimated $85M increase.
  • Candriam SCA's biggest Q2 2025 reduction was Tesla, cutting an estimated $80.5M.
  • Candriam SCA fully exited Banco Macro in Q2 2025, selling an estimated $17.6M.
  • Candriam SCA's ten largest holdings make up 32% of its $17.3B portfolio in Q2 2025.
  • Candriam SCA opened 61 new positions and closed 55 in Q2 2025.
  • Candriam SCA's portfolio value rose 8.6% quarter-over-quarter to $17.3B.

Based on Candriam SCA's 13F filing for Q2 2025, filed 8 Aug 2025.